Search

Search Constraints

You searched for: Author/Creator Izzi, A.

Search Results

1. Daclatasvir/sofosbuvir and ribavirin 800 mg flat dose is highly efficacy and safe in genotype 3 compensated and decompensated cirrhotic patients: The CLEO experience. Issue 1 (16th February 2017)

2. Impact of different Sofosbuvir-based direct acting antiviral (DAA) regimen in elderly cirrhotic patients: A real world experience from CLEO Group. (10th February 2016)

3. Intracranial pressure monitoring in patients with acute brain injury in the intensive care unit (SYNAPSE-ICU): an international, prospective observational cohort study. Issue 7 (July 2021)

4. Late HCC onset after direct antiviral agents therapy in patients with sustained virological response: do we need to reconsider their efficacy according to long term follow-up?. (3rd August 2018)

5. Long-term results from the Italian real-world experience on obeticholic acid treatment in primary biliary cholangitis: The RECAPITULATE study. (March 2023)

6. Prediction of response to obeticholic acid in primary biliary cholangitis: Development and validation of the OCA response score (ORS). (March 2023)

7. Real-world data on the treatment of primary biliary cholangitis with obeticholic acid in Italy: the CLEO-AIGO OCA cohort. (February 2020)